Next 10 |
2024-06-24 07:00:00 ET Summary Nuvalent, Inc. is a biotechnology company with precision-targeted treatments using kinase inhibitors for non-small cell lung cancer. NVL-520 targets ROS1-positive cancer and addresses treatment resistance, kinase mutations, and CNS-related adverse ev...
2024-06-14 07:15:55 ET Summary Nuvalent's NVL-655 received FDA Breakthrough Therapy Designation for ALK+ NSCLC, showing potential as a vital therapy. Nuvalent's pipeline includes innovative kinase therapies for NSCLC, with NVL-655 and Zidesamtinib showing promise in clinical trial...
2024-06-13 14:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Nuvalent to Participate in the 2024 Jefferies Global Healthcare Conference PR Newswire CAMBRIDGE, Mass. , May 29, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapi...
2024-05-16 16:18:34 ET More on Nuvalent Nuvalent: Pivotal NSCLC Programs Progressing With Additional Data In 2024 Jefferies starts Nuvalent at buy, cites lung cancer drug candidates Nuvalent lung cancer candidate gets FDA breakthrough therapy status Seeking A...
Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-655 PR Newswire CAMBRIDGE, Mass. , May 16, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therap...
2024-05-09 10:59:16 ET More on Nuvalent Nuvalent: Pivotal NSCLC Programs Progressing With Additional Data In 2024 Jefferies starts Nuvalent at buy, cites lung cancer drug candidates Nuvalent lung cancer candidate gets FDA breakthrough therapy status Read th...
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial Results PR Newswire Updates from the ongoing Phase 1/2 ARROS-1 and ALKOVE-1 clinical trials expected at a medical meeting in the second half of 2024 S...
2024-04-18 09:54:06 ET More on Nuvalent Nuvalent: Pivotal NSCLC Programs Progressing With Additional Data In 2024 Nuvalent lung cancer candidate gets FDA breakthrough therapy status Baird starts Nuvalent at outperform, cites potential of lead assets Seeking A...
2024-04-13 13:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
News, Short Squeeze, Breakout and More Instantly...
2024-06-13 14:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Nuvalent to Participate in the 2024 Jefferies Global Healthcare Conference PR Newswire CAMBRIDGE, Mass. , May 29, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapi...
Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-655 PR Newswire CAMBRIDGE, Mass. , May 16, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therap...